InvestSMART

Genetic Signatures Limited (ASX:GSS)

ALERT: Price-sensitive ASX Announcement for GSS
Current share price for GSS : $0.060 -0.08 (-57.14%)+
Announcement
Release
15 Apr 2026 4:37PM
Price at Release
$0.140
Full Release
download
Summary
Genetic Signatures Limited announced additional information regarding a Danish supply agreement, which is expected to account for approximately 6% of their annual sales based on current estimates. This agreement is strategically important as it provides a long-term revenue stream, diversifies their customer base in the EMEA region, and aligns with the company's growth objectives. The contract is legally binding without any remaining conditions and is anticipated to result in commercial orders by September 2026. Genetic Signatures, an Australian molecular diagnostics company, is known for its 3base® technology that simplifies pathogen detection. They market their EasyScreen™ diagnostic assays internationally, expanding in regions like Europe and the Asia-Pacific.
Key Points
  • The Danish supply agreement is expected to represent approximately 6% of the company's current sales over a twelve-month period.
  • The agreement is considered meaningful for the company's operations, providing a long-term and recurring revenue contribution in EMEA.
  • The contract diversifies Genetic Signatures' customer base and aligns with its growth strategy.
  • The contract is legally binding with no outstanding conditions precedent, and commercial orders are expected from September 2026.
  • Genetic Signatures is an Australian molecular diagnostics company focusing on infectious disease detection using its proprietary 3base® technology.
  • The company's EasyScreen™ diagnostic assays are marketed globally, with a growing presence in Europe, the UK, and the Asia-Pacific region.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.